Durvalumab,Carboplatin,Paclitaxel,Cisplatin,Gemcitabine,Pemetrexed
Astrazeneca
['nsclc', 'imfinzi', 'sclc', '$azn']
imfinzi reduces risk of recurrence, progression by 32% in patients with resectable nsclc #aacr23 $azn 
The latest global #pharma news, insights, analysis, and views providing you with an information edge.  FirstWord Pharma. Where people who know first, go first.